1. Home
  2. TLS vs CABA Comparison

TLS vs CABA Comparison

Compare TLS & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Telos Corporation

TLS

Telos Corporation

HOLD

Current Price

$4.44

Market Cap

317.1M

Sector

Technology

ML Signal

HOLD

Logo Cabaletta Bio Inc.

CABA

Cabaletta Bio Inc.

HOLD

Current Price

$3.33

Market Cap

319.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TLS
CABA
Founded
1969
2017
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
317.1M
319.6M
IPO Year
2020
2019

Fundamental Metrics

Financial Performance
Metric
TLS
CABA
Price
$4.44
$3.33
Analyst Decision
Buy
Strong Buy
Analyst Count
5
6
Target Price
$7.90
$14.50
AVG Volume (30 Days)
680.8K
1.9M
Earning Date
05-08-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
31.51
10.26
EPS
N/A
N/A
Revenue
$164,805,000.00
N/A
Revenue This Year
$18.72
N/A
Revenue Next Year
$14.62
N/A
P/E Ratio
N/A
N/A
Revenue Growth
52.21
N/A
52 Week Low
$1.83
$1.06
52 Week High
$8.36
$3.78

Technical Indicators

Market Signals
Indicator
TLS
CABA
Relative Strength Index (RSI) 56.06 63.99
Support Level $3.80 $2.32
Resistance Level $4.61 $3.73
Average True Range (ATR) 0.20 0.20
MACD 0.02 0.06
Stochastic Oscillator 85.25 99.48

Price Performance

Historical Comparison
TLS
CABA

About TLS Telos Corporation

Telos Corp offers technologically forwarded, software-based security solutions that empower and protect the world's security-conscious organizations against rapidly evolving, sophisticated, and pervasive threats. Its business has two reportable and operating segments namely Security Solutions and Secure Networks. The Security Solutions segment focuses on cybersecurity, cloud, and identity solutions, and the Secure Networks focuses on enterprise security. The company derives maximum revenue from the Security Solutions segment.

About CABA Cabaletta Bio Inc.

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.

Share on Social Networks: